Evidence map›Paper›PMID 38211884›Full record

ArticleJournal of advanced research2024

Therapeutic effect of phycocyanin on chronic obstructive pulmonary disease in mice.

Wenjun Li, Yuanyuan Li, Qi Wang, Runze Liu, Jianing Lu, Wenju Lu, Song Qin

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Molecules (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Research Progress on Animal Models of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Toxicological assessment ofFrontiers in toxicology · 2025
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Wenjun LiYantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China; Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China.
Yuanyuan LiGuangzhou Medical University, Guangzhou 510030, China; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institue of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510031, China.
Qi WangYantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China; Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China.
Runze LiuYantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.
Jianing LuGuangzhou Medical University, Guangzhou 510030, China.
Wenju LuGuangzhou Medical University, Guangzhou 510030, China; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institue of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510031, China. Electronic address: wlu92@gzhmu.edu.cn.
Song QinYantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China; Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China. Electronic address: sqin@yic.an.cn.
Shandong University of Traditional Chinese Medicine · CNSecond Affiliated Hospital of Guangzhou Medical University · CNChinese Academy of Sciences · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe prevention and treatment of chronic obstructive pulmonary disease (COPD) is closely tied to antioxidation and anti-inflammation. Phycocyanin (PC) has numerous pharmacological effects, such as antioxidation and anti-inflammation. However, it remains unclear whether PC can play a therapeutic role in COPD.

objectiveAs inflammation and oxidative stress can aggravate COPD, this study is to explore the effect of PC on COPD mice and its mechanisms.

methodsThe COPD mice model was established by exposing them to lipopolysaccharide (LPS) and cigarette smoke (CS); PC was administrated in a concentration of 50 mg/kg for 30 days. On the last day, lung function was measured, and bronchoalveolar lavage fluid (BALF) was obtained and classified for cells. Lung tissue pathological change was analyzed, and organ indices statistics were measured. Based on molecular docking, the mechanism was explored with Western blotting, immunohistochemical, and immunofluorescence in vivo and in vitro.

resultsPC significantly ameliorated the pulmonary function of COPD mice and reduced inflammation of the lung (p < 0.05), and hematoxylin and eosin (H&E) staining showed PC depressed lung inflammatory cell accumulation and emphysema. Periodic acid Schiff (PAS) and Masson staining revealed that PC retarded goblet cells metaplasia and collagen deposition (p < 0.05). In addition, in vivo PC regulated Heme oxygenase 1 (HO-1) (p < 0.05) and NAD(P)H dehydrogenase quinone 1 (NQO1) level (p < 0.01) in the lung, as well as NOX2 level in pulmonary macrophages. Molecular docking results indicate that phycocyanobilin (PCB) in PC had a good binding site in Keap1 and NOX2 proteins; the phycocyanobilin-bound phycocyanin peptide (PCB-PC-peptide) was obtained for further studies. In vitro, PCB-PC-peptide could depress the phospho-NF-E2-related factor 2 (p-Nrf2) and NQO1 protein expression in RAW264.7 cells induced by cigarette smoke extract (CSE) (p < 0.05).

conclusionPC exerts beneficial effects on COPD via anti-inflammatory and antioxidative stress, which may be achieved through PCB.

Indexed as

LungOxidative StressPhycocyaninPulmonary Disease, Chronic ObstructiveAnimalsAnti-Inflammatory AgentsAntioxidantsBronchoalveolar Lavage FluidDisease Models, AnimalInflammationLipopolysaccharidesMaleMiceMice, Inbred C57BLMolecular Docking SimulationRAW 264.7 CellsAnti-Inflammatory AgentsAntioxidantsLipopolysaccharidesPhycocyaninAnti-inflammatory drugsAntioxidantsChronic obstructive pulmonary diseasePhycocyanin

Identifiers

PMID38211884
PMCPMC11675062
OpenAlexW4390782935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.